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Editorial on the Research Topic
Inflammatory Signaling in Bone Marrow Failure and Hematopoietic Malignancy
In response to inflammatory stimuli (e.g., infection and injury) hematopoietic stem and progenitor 
cells (HSPCs) proliferate and differentiate, giving rise to the effector cell types necessary to fight the 
acute insult. While this is an important part of the normal immune response, sustained or aber-
rant exposure to inflammatory signals can lead to a loss of HSPC function. Accumulating reports 
demonstrate that inflammatory cytokines (e.g., IFNγ, IFNα/β, and TNFα), and even pathogens or 
cell damage-associated ligands, can influence the function of HSPCs via both direct and indirect 
mechanisms and may contribute to clinically significant disorders of HSPCs including bone marrow 
(BM) failure and hematopoietic malignancies.
In this topic, we explore the effects of infections and their associated inflammatory cytokines on 
HSPCs. The seven reviews and one original article within this topic cover the role of inflammatory 
signals in regulating HSPCs from their ontogeny through old age and discuss the contribution of 
these signals to BM dysfunction and leukemogenesis. Furthermore, they highlight the unique effects 
of different pathogens and cytokines on HSPCs and discuss the direct, cell-autonomous effects of 
inflammation on HSPCs versus the indirect effects that are mediated by alterations in stromal cells 
and other cells within the BM microenvironment.
To start, a review by Clapes et al. discusses recent reports implicating a role for inflammatory 
signals in the emergence of hematopoietic stem cells (HSCs) during embryogenesis. Studies in 
zebrafish and mice have identified TNFα, IFNγ, IL1β, and Toll-like receptor 4 as important regula-
tors of HSC ontogeny. These signals ultimately activate NF-κB, which is essential for HSC specifica-
tion in the normal endothelial-to-hematopoietic transition. After their emergence, inflammatory 
signals continue to influence HSCs and progenitors throughout the lifetime of an organism, and, 
as discussed in a review by Kovtonyuk et al. on the “inflamm-aging” of hematopoiesis, they may 
contribute to the phenotype of aged HSPCs (e.g., decreased self-renewal and myeloid differentia-
tion bias).
The next four articles in this topic focus on different aspects of how inflammatory signals affect 
HSPCs and contribute to BM suppression. Pascutti et  al. discuss the direct and indirect impact 
of viral infections on HSPCs, noting that while such infections influence hematopoietic output in 
the short term, they may also contribute to BM pathologies such as cytopenias and malignancies 
(particularly when chronic). They point out that many different viral infections give rise to the same 
pathologies (e.g., pancytopenia), suggesting that common mechanisms of viral or immunological 
origin are responsible. On the other hand, they note that the same virus can have very different 
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pathological manifestations in diverse individuals, suggesting 
that there are also genetic differences that contribute to the risk 
for BM pathologies in response to infection. Next, Smith et al. 
discuss the direct and indirect, or niche-mediated, effects of 
interferons on HSPCs, and their contribution to the pathogenesis 
of acquired aplastic anemia (AA). Patients with acquired AA have 
been shown to have elevated levels of IFNγ (1), which may impair 
HSPCs directly through a block in self-renewal and promotion of 
apoptosis, as well as indirectly via effects on cells of the microen-
vironment including macrophages, mesenchymal stromal cells, 
and T cells. The role of type I IFNs in AA is less clear; however, 
they may also both directly and indirectly affect HSPC function 
and may synergize with IFNγ in suppressing HSPCs and lead-
ing to BM failure. Highlighting the indirect effects of pathogens 
and inflammatory cytokines on HSPCs, a review by Nombela-
Arrieta and Isringhausen focuses on the effects of these signals 
on the stromal cells of the BM microenvironment, noting that 
these effects are unique to individual pathogens and involve a 
variety of stromal cell subsets. For example, infections can target 
mesenchymal stromal cells, osteoblasts, endothelial cells, and 
others within the BM, influencing their survival and function via 
direct infection and/or indirect effects on supporting cytokines. 
Finally, Masouridi-Levrat et  al. describe the contribution of 
chronic inflammation to poor graft function in individuals who 
have received an allogeneic HSC transplant. Inflammatory condi-
tions such as graft-versus-host disease or infections can impair 
HSPC self-renewal and proliferation, in part, via upregulation of 
cytokines such as IFNγ and TNFα and the induction of apoptosis 
through Fas/Fas ligand signaling. Together, these four review arti-
cles emphasize the role of pathogens and inflammatory cytokines 
in BM suppression and suggest that interruption of these signals 
may have therapeutic benefit toward improving HSPC function 
in patients with chronic inflammatory conditions.
The last two papers in this topic focus on the contribution of 
inflammation to hematopoietic malignancy. Monlish et al. review 
the role of toll like receptor (TLR) signaling in myelodysplastic 
syndromes (MDS) and leukemias. Enhanced TLR expression 
and/or signaling has been described in multiple hematopoietic 
malignancies and may contribute to the pathogenesis of these 
diseases via both cell-autonomous and non-autonomous mecha-
nisms. In the final article of the topic, Balandran et al. present 
original data demonstrating that mesenchymal stromal cells 
from pediatric patients with acute lymphoblastic leukemia differ 
from their normal counterparts, producing pro-inflammatory 
cytokines and displaying reduced amounts of CXCL12 and SCF. 
These changes, while detrimental to normal HSPCs, confer a 
growth advantage to leukemic precursor cells. Thus, these articles 
highlight aberrant inflammatory signaling in the premalignant 
cells and their microenvironment as potential therapeutic targets 
in patients with MDS and leukemia.
In summary, we have learned much in recent years regarding 
the effects of inflammatory signals on HSPCs and their contribu-
tion to BM failure and hematopoietic malignancies. However, as 
discussed throughout this topic, there are still open questions 
regarding the mechanisms by which these signals exert their 
effects, as well as understanding the balance between “normal” 
inflammatory signals that help shape the evolving immune system 
and contribute to an effective immune response to insult versus 
those that cause sustained damage to HSPCs. Continued research 
into these questions will hopefully lead to new therapeutic targets 
to improve BM function and inhibit transformation in patients 
with chronic or aberrant inflammation.
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